Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07033299

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

A Clinical Study Exploring the Safety, Efficacy, and Cellular Metabolic Kinetics of Universal CD19/20 CAR-T Cell Injection in Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

Sponsor: CARsgen Therapeutics Co., Ltd.

Conditions ANCA Associated Vasculitis (AAV)

Interventions CAR-T Therapy

Updated 3 times since 2025 Last updated: Jun 23, 2025 Started: Jul 1, 2025 Primary completion: Dec 31, 2026 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates ANCA Associated Vasculitis (AAV) and is currently actively recruiting participants. CARsgen Therapeutics Co., Ltd. leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CARsgen Therapeutics Co., Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Data source: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China